Avalyn Pharma (AVLN)

The company’s approach is to reformulate established anti-fibrotic medicines for inhaled delivery. By delivering therapy directly to the lungs, Avalyn aims to increase local exposure in the affected tissue while potentially reducing systemic side effects that can limit tolerability for some patients. This targeted-delivery concept is central to its pipeline and differentiates the company from developers of conventional oral or systemic therapies for pulmonary fibrosis.

Avalyn’s lead programmes include AP01, an inhaled formulation of pirfenidone, and AP02, an inhaled formulation of nintedanib. Both underlying medicines are known anti-fibrotic agents used in lung fibrosis treatment, and Avalyn is developing inhaled versions for conditions such as idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. Idiopathic pulmonary fibrosis is among the best-known forms of interstitial lung disease and is characterised by worsening scarring without a clearly identified cause. Progressive pulmonary fibrosis refers to a broader group of fibrotic lung diseases that continue to advance despite standard management.

Avalyn operates as a focused rare lung disease company, with one reportable business segment dedicated to developing and commercialising targeted therapies for these conditions. Its prospects depend on clinical trial results, regulatory review, manufacturing execution, and the ability to demonstrate that inhaled anti-fibrotic therapy can meaningfully improve the treatment landscape for patients with severe lung disease.